The primary objective of this study is to compare the safety and efficacy of Brimonidine Tartrate Ophthalmic Solution, 0.15% in patients with open-angle glaucoma or ocular hypertension...
Date First Received: May 28, 2003
Last Updated: August 4, 2008
Verified by: Alcon Research, August 2008
Clinical Trial Phase: Phase 3 | Start Date: January 2003
Overall Status: Completed
Brief Summary
Official Title: “A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension”
Condition Keyword(s):
Intervention(s):
The primary objective of this study is to compare the safety and efficacy of Brimonidine Tartrate Ophthalmic Solution, 0.15% in patients with open-angle glaucoma or ocular hypertension.
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Study Primary Completion Date: July 2004
Intervention(s) in this Clinical Trial
- Drug: Brimonidine Tartrate Ophthalmic Solution
Criteria for Participation in this Clinical Trial
- Patients of any race
- two (2) years of age or older
- of either sex
- diagnosed with open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component)or ocular hypertension
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 2 Months
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Alcon Research
Additional Information
Information obtained from ClinicalTrials.gov on November 19, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00061529
Study ID Number: C-02-49
ClinicalTrials.gov Identifier: NCT00061529
Health Authority: United States: Food and Drug Administration
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
